New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.
Scott A. Wilke, MD, PhD
Advertisement
Scott A. Wilke, MD, PhD, an assistant professor of psychiatry and the Penske Family Chair in Neuromodulation at UCLA Health.
Articles by Scott A. Wilke, MD, PhD
In a Q&A, psychiatrist Scott Wilke, MD, explains how accelerated TMS protocols are reshaping depression care and may help tailor treatment to specific neural circuits.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome
2
The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH
3
Hereditary Angioedema Triggers, Prodromes Mapped in US HAEA Registry
4
Weekly Insulin Efsitora Alfa (Onswik) Gains FDA approval for Type 2 Diabetes
5